At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for ...
At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen ...
At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global ...
At the GRx+Biosims 2024 conference, panelists explored challenges and progress in biosimilar interchangeability regulations ...
Sarfaraz K. Niazi, PhD, provides an overview of the current biosimilar education material offered by the FDA, emphasizing ...
Sophia Humphreys, PharmD, from Sutter Health explains that expanding biosimilars into new therapeutic areas faces hesitance ...
A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17(Samsung Bioepis) to the reference ...
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...
Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment ...
Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback